RYTM logo

RYTM
Rhythm Pharmaceuticals Inc.

2,056
Mkt Cap
$5.85B
Volume
21,629.00
52W High
$122.20
52W Low
$55.31
PE Ratio
-27.57
RYTM Fundamentals
Price
$86.75
Prev Close
$85.70
Open
$86.13
50D MA
$89.76
Beta
1.00
Avg. Volume
1.11M
EPS (Annual)
-$3.11
P/B
41.41
Rev/Employee
$458,350.24
$6,810.11
Loading...
Loading...
News
all
press releases
Universal Beteiligungs und Servicegesellschaft mbH Increases Stock Holdings in Rhythm Pharmaceuticals, Inc. $RYTM
Universal Beteiligungs und Servicegesellschaft mbH increased its holdings in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 21.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owne...
MarketBeat·1d ago
News Placeholder
More News
News Placeholder
M&T Bank Corp Invests $9.20 Million in Rhythm Pharmaceuticals, Inc. $RYTM
M&T Bank Corp acquired a new position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities...
MarketBeat·2d ago
News Placeholder
Rhythm Pharmaceuticals (NASDAQ:RYTM) Lowered to Sell Rating by Wall Street Zen
Wall Street Zen lowered shares of Rhythm Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Sunday...
MarketBeat·8d ago
News Placeholder
Wall Street Zen Upgrades Rhythm Pharmaceuticals (NASDAQ:RYTM) to Hold
Wall Street Zen upgraded Rhythm Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Saturday...
MarketBeat·16d ago
News Placeholder
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives Average Recommendation of "Moderate Buy" from Analysts
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Get Free Report) has been assigned an average rating of "Moderate Buy" from the nineteen analysts that are presently covering the company, MarketBeat.com...
MarketBeat·19d ago
News Placeholder
Rhythm Pharma Appoints Kim Popovits To Board; Ed Mathers To Depart
(RTTNews) - Rhythm Pharmaceuticals Inc. (RYTM) on Friday announced the appointment of Kim Popovits to its board of directors...
Nasdaq News: Markets·24d ago
News Placeholder
Hennion & Walsh Asset Management Inc. Trims Stock Holdings in Rhythm Pharmaceuticals, Inc. $RYTM
Hennion & Walsh Asset Management Inc. lowered its stake in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 75.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned...
MarketBeat·24d ago
News Placeholder
Strength Seen in Rhythm Pharmaceuticals (RYTM): Can Its 12.6% Jump Turn into More Strength?
Rhythm Pharmaceuticals (RYTM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks·26d ago
News Placeholder
Rhythm Pharmaceuticals (NASDAQ:RYTM) Trading 10.9% Higher - Should You Buy?
Rhythm Pharmaceuticals (NASDAQ:RYTM) Trading Up 10.9% - Here's Why...
MarketBeat·27d ago
News Placeholder
Rhythm Pharmaceuticals Wins FDA Approval for IMCIVREE in Acquired Hypothalamic Obesity Launch
Rhythm Pharmaceuticals (NASDAQ:RYTM) announced that the U.S. Food and Drug Administration has approved IMCIVREE (setmelanotide) for patients with acquired hypothalamic obesity, according to...
MarketBeat·1mo ago
<
1
2
...
>

Latest RYTM News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.